Table 2.

Description of disease relapses in the abatacept and placebo study arms.

Disease Features at relapse		ESR mm/hr	CRP mg/dl	Prednisone Dose at relapse (mg)	Last infusion (week)
ABATACEPT
1	Leg extremity claudication, malaise	74	9.5	15	12
2	Arthralgias, malaise	92	90.9	0	60
3	Arthralgias, skin lesions	52	12.3	4	20
4	Arthralgias, erythema nodosum	98	99.2	0	32
5	Leg claudication, headache, malaise	30	116.0	9	20
6	Carotidynia, jaw/tongue claudication, leg claudication	41	20.7	15	12
7	Arthralgias, malaise, fatigue, myalgias	44	60.1	12.5	16
8	Carotidynia, fatigue, malaise	25	33.6	0	44
PLACEBO
1	Vascular back pain	76	9.6	7	20
2	New vascular stenosis	53	3.2	0	36
3	Arthralgias, malaise, myalgias	43	50.8	0	84
4	Headache, scalp pain, arthralgias, arthritis, artery pain, malaise	33	2.6	0	28
5	Pericarditis, myalgias, malaise	50	1.6	0	32
6	New vascular stenosis	31	20.9	0	32
7	Headache, carotidynia	80	69.8	0	32
8	Jaw/tongue claudication, blurred vision, dizziness	ND	ND	6	24
9	Leg claudication, arthralgia, mesenteric ischemia, melena, malaise	30	15.4	1	24
10	New vascular stenosis, venous thrombosis	129	9.2	0	44

CRP: C reactive protein; ESR: erythrocyte sedimentation rate, ND: not done